Eckert & Ziegler to join Chinese-German pharma development joint venture

23-Jul-2013 - Germany

Eckert & Ziegler AG by its subsidiary Eckert & Ziegler Radiopharma GmbH will acquire a minority interest in OctreoPharm Sciences GmbH, a company specialized in radiopharmaceuticals for nuclear medicine. OctreoPharm Sciences focuses on the clinical development of new types of radiopharmaceuticals for diagnostics and treatment in the field of oncology.

OctreoPharm Sciences has various peptides currently in pre-clinical development as a potential solution for the detection of neuroendocrine tumors using positron emission tomography (PET). Depending on the radionuclide it is coupled with, it could be used both in diagnosing (gallium-68) and treating (yttrium-90) such tumors. Clinical testing on humans (phase I) is slated to begin towards the end of next year.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...